1108 Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–IL–08]; 

9. Japanese Patent No. 6742991 issued 

August 19, 2020, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–JP–09]; 

10. Korean Patent No. 10–2445667 issued 

September 16, 2022, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–KR–10]; 

11. Mexican Patent No. 375379 issued 

September 25, 2020, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–MX–11]; 

12. Saudi Arabian Patent No. 7456 issued 

January 5, 2021, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–SA–12]; 

13. United States Patent No. 10,174,098 

issued January 8, 2019, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–US–13]; 

14. Hong Kong Patent No. HK1236203 

issued January 8, 2021, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–HK–14]; 

15. United States Patent No. 10,870,687 

issued December 22, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–US–15]; 

16. European Patent Application No. 

19217074.4 filed December 17, 2019, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–EP–16]; 

17. Australian Patent No. 2019283892 

issued May 13, 2021, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–AU–17]; 

18. Japanese Patent No. 6997267 issued 

December 20, 2021, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–JP–53]; 

19. Saudi Arabian Patent Application No. 

520412601 filed August 10, 2020, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–SA–54]; 

20. Hong Kong Patent Application No. 

42020020661.3 filed November 24, 2020, 

entitled ‘‘Anti-Human Papillomavirus 16 E7 

T Cell Receptors’’ [HHS Reference No. E– 

176–2014–0–HK–55]; 

21. Mexican Patent Application No. MX/a/ 

2020/010035 filed September 24, 2020, 

entitled ‘‘Anti-Human Papillomavirus 16 E7 

T Cell Receptors’’ [HHS Reference No. E– 

176–2014–0–MX–56]; 

22. United States Patent No. 11,434,272 

issued September 6, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–US–57]; 

23. Australian Patent No. 2021202227 

issued February 23, 2023, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–AU–58]; 

24. Chinese Patent Application No. 

20210399056.9 filed April 14, 2021, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–CN–59]; 

25. Israeli Patent No. 282518 issued July 2, 

2022, entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference No. 

E–176–2014–0–IL–60]; 

26. Hong Kong Patent Application No. 

42022046605.6 filed January 19, 2022, 

entitled ‘‘Anti-Human Papillomavirus 16 E7 

T Cell Receptors’’ [HHS Reference No. E– 

176–2014–0–HK–62]; 

27. Japanese Patent No. 7291196 issued 

June 6, 2023, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–JP–63]; 

28. Israeli Patent Application No. 290655 

filed February 16, 2022, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–IL–64]; 

29. United States Patent Application No. 

17/816,496 filed August 1, 2022, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–US–65]; 

30. Korean Patent Application No. 2022– 

7032043 filed September 15, 2022, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–KR–66]; 

31. Australian Patent Application No. 

2023200608 filed February 6, 2023, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–AU–01]; and 

32. Japanese Patent Application No. 2023– 

091878 filed June 2, 2023, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–JP–01]. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the 

following: 

‘‘Thermally controlled autologous T 

cell therapy products for the treatment 

of HPV-positive cancer in humans.’’ 

The E–176–2014 patent family is 

primarily directed to an isolated TCR 

reactive to HPV 16 E7 antigen in the 

context of HLA–A*02:01 (the ‘‘E7 

TCR’’). HPV describes a group of human 

viruses known to cause malignancy. Of 

the group, HPV–16 is the most prevalent 

strain. Approximately 90% of adults are 

estimated to have been exposed at some 

point in their lifetime. HPV drives 

transformation of infected cells through 

the expression of certain oncoproteins, 

chiefly E5, E6 and E7. The latter two are 

constitutively expressed in malignant 

cells and are necessary to maintain a 

transformed state, rendering them 

attractive therapeutic targets. 

The E7 TCR may be useful in the 

development of certain diagnostics and/ 

or therapeutics for the treatment of 

cancers which express both the HPV 16 

E7 oncoprotein and HLA–A*02:01. 

Potential therapeutic applications of the 

E7 TCR may include, but are not limited 

to, engineered autologous or allogeneic 

immune cell therapies (e.g., T cell or 

natural killer cell-based) and TCR fusion 

proteins and conjugates (e.g., soluble 

TCR bi-specifics or TCR-drug 

conjugates). The exclusive field of use 

which may be granted to Port applies to 

‘‘thermally controlled’’ autologous T 

cell products, which is a subset of 

engineered immune cell therapies. 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: January 4, 2024. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2024–00209 Filed 1–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Council of Councils. 

The meeting will be held as a virtual 

meeting open to the public as indicated 

below, with attendance limited to space 

available. Individuals who plan to 

attend as well as those who need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, must notify the 

Contact Person listed below in advance 

of the meeting. The open session will be 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices 1109 

videocast and can be accessed from the 

NIH Videocasting and Podcasting 

website (http://videocast.nih.gov/). 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Council of Councils. 

Date: January 25–26, 2024. 

Open: January 25, 2024, 10:00 a.m. to 3:45 

p.m. 

Agenda: Welcome and Opening Remarks; 

Announcements; NIH Program Updates; 

Strategic Plans; and Other Business of the 

Committee. 

Place: National Institutes of Health, 

Building 1, 1 Center Drive, Bethesda, MD 

20892 (Virtual Meeting). 

Closed: January 25, 2024, 4:00 p.m. to 5:00 

p.m. 

Agenda: Review of Grant Applications. 

Place: National Institutes of Health, 

Building 1, 1 Center Drive, Bethesda, MD 

20892 (Virtual Meeting). 

Open: January 26, 2024, 10:15 a.m. to 3:15 

p.m. 

Agenda: Strategic Plans; and Other 

Business of the Committee. 

Place: National Institutes of Health, 

Building 1, 1 Center Drive, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Franziska Grieder, D.V.M., 

Ph.D., Executive Secretary, Council of 

Councils, Director, Office of Research 

Infrastructure Programs, Division of Program 

Coordination, Planning, and Strategic 

Initiatives, Office of the Director, NIH, 6701 

Democracy Boulevard, Room 948, Bethesda, 

MD 20892, GriederF@mail.nih.gov, 301–435– 

0744. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Council of Council’s home page at http://

dpcpsi.nih.gov/council/ where an agenda 

will be posted before the meeting date. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: January 4, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–00247 Filed 1–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2024–1 Phase I: Development of a Serological 

Test for Herpes Simplex Types 1 and 2 

Infections (Topic 133). 

Date: February 6, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52A, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Shilpakala Ketha, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3F52A, Rockville, MD 

20852, (301) 761–6821, shilpa.ketha@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 3, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00200 Filed 1–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Biomedical 

Imaging and Bioengineering; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings of the National 

Institute of Biomedical Imaging and 

Bioengineering Special Emphasis Panel. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Biomedical Imaging and Bioengineering 

Special Emphasis Panel; Career Development 

(Ks) and Conference support (R13) Review. 

Date: February 22, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Dem II, 

Suite 920, 6707 Democracy Boulevard, 

Bethesda, MD 20817 (Virtual Meeting). 

Contact Person: Tianhong Wang, MD, 

Ph.D., Scientific Review Officer, National 

Institute of Biomedical Imaging and 

Bioengineering, National Institutes of Health, 

6707 Democracy Blvd., Bethesda, MD 20892, 

(301) 435–1189, wangt3@mail.nih.gov. 

Name of Committee: National Institute of 

Biomedical Imaging and Bioengineering 

Special Emphasis Panel; P41 NCBIB Review 

D–SEP. 

Date: March 20–22, 2024. 

Time: 9:30 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Dem II, 

Suite 920, 6707 Democracy Blvd., Bethesda, 

MD 20817 (Virtual Meeting). 

Contact Person: John K. Hayes, Ph.D., 

Scientific Review Officer, National Institute 

of Biomedical Imaging and Bioengineering, 

National Institutes of Health, 6707 

Democracy Blvd., Suite 959, Bethesda, MD 

20892, (301) 451–3398, hayesj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, National Institute of 

Biomedical Imaging and Bioengineering, 

National Institutes of Health.) 

Dated: January 4, 2024. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00208 Filed 1–8–24; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES